CY1104986T1 - Σταθερα σκευασματα παραγοντα viii - Google Patents

Σταθερα σκευασματα παραγοντα viii

Info

Publication number
CY1104986T1
CY1104986T1 CY20061100247T CY061100247T CY1104986T1 CY 1104986 T1 CY1104986 T1 CY 1104986T1 CY 20061100247 T CY20061100247 T CY 20061100247T CY 061100247 T CY061100247 T CY 061100247T CY 1104986 T1 CY1104986 T1 CY 1104986T1
Authority
CY
Cyprus
Prior art keywords
ions
factor viii
mammalian cells
optionally
divalent metal
Prior art date
Application number
CY20061100247T
Other languages
English (en)
Inventor
Marianne Mikaelsson
Helena Sandberg
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1104986(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9902685A external-priority patent/SE9902685D0/xx
Priority claimed from SE0001743A external-priority patent/SE0001743D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of CY1104986T1 publication Critical patent/CY1104986T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα φαρμακευτικό σκεύασμα που περιέχει Παράγοντα VIII και τα δισθενή μεταλλικά ιόντα Ζn2+ και Cu2+, προαιρετικώς παρουσία ιόντων Ca2+ και/ή ιόντων Μn2+, όπου ο αναφερόμενος Παράγοντας VIII είναι σταθερός χωρίς την προσθήκη αλβουμίνης. Η εφεύρεση επίσης σχετίζεται με μια μέθοδο παραγωγής ανασυνδυασμένου Παράγοντα VIII από κύτταρα θηλαστικών που φέρουν το γονίδιο αυτού, που περιλαμβάνει καλλιέργεια των αναφερόμενων κυττάρων θηλαστικών σε ένα θρεπτικό μέσο ελεύθερο από πρωτεΐνη που προέρχεται από πλάσμα και εμπλουτισμένο με δισθενή μεταλλικά ιόντα, συμπεριλαμβανομένου Cu2+ και Ζn2+, και προαιρετικώς παρουσία ιόντων Ca2+ και Μn2+.
CY20061100247T 1999-07-13 2006-02-21 Σταθερα σκευασματα παραγοντα viii CY1104986T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9902685A SE9902685D0 (sv) 1999-07-13 1999-07-13 Stable protein compositions
US14682899P 1999-08-02 1999-08-02
SE0001743A SE0001743D0 (sv) 2000-05-11 2000-05-11 Stable protein compositions II
PCT/SE2000/001454 WO2001003726A1 (en) 1999-07-13 2000-07-07 Stable factor viii compositions

Publications (1)

Publication Number Publication Date
CY1104986T1 true CY1104986T1 (el) 2009-11-04

Family

ID=27354553

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100247T CY1104986T1 (el) 1999-07-13 2006-02-21 Σταθερα σκευασματα παραγοντα viii

Country Status (14)

Country Link
US (1) US6599724B1 (el)
EP (1) EP1194161B1 (el)
JP (1) JP4674021B2 (el)
AR (1) AR024735A1 (el)
AT (1) ATE310533T1 (el)
AU (1) AU780415B2 (el)
CA (1) CA2378751C (el)
CY (1) CY1104986T1 (el)
DE (1) DE60024268T2 (el)
DK (1) DK1194161T3 (el)
ES (1) ES2252028T3 (el)
NO (1) NO330048B1 (el)
NZ (1) NZ516400A (el)
WO (1) WO2001003726A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
CA2470511C (en) 2001-12-21 2014-05-27 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
DE60314667T3 (de) † 2002-12-27 2019-12-05 Japan Cash Machine Co., Ltd. Optische messvorrichtung zur bestimmung optischer merkmale von wertpapieren
KR20050110682A (ko) * 2003-03-18 2005-11-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
DE602004026474D1 (de) * 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
EP3378470A1 (en) * 2003-12-19 2018-09-26 Novo Nordisk Health Care AG Stabilised compositions of factor vii polypeptides
US7422875B2 (en) * 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US20090017007A1 (en) * 2005-08-26 2009-01-15 Maxygen Holdings Ltd. Liquid factor vii composition
FR2908892B1 (fr) * 2006-11-21 2009-02-20 Hyphen Biomed Soc Par Actions Procede pour le dosage chromogenique de l'activite du facteur viii:c et necessaire de dosage chromogenique de l'activite du facteur viii:c,dans les plasmas ou les fractions therapeutiques
CN101965409A (zh) 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
SG10201503304RA (en) 2007-12-27 2015-06-29 Baxter Int Cell culture processes
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
US9115381B2 (en) * 2011-05-13 2015-08-25 Octapharma Ag Method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
US9855319B2 (en) 2014-04-01 2018-01-02 Advantech Bioscience Farmacêutica Ltda Stabilization of factor VIII without calcium as an excipient
WO2015149143A2 (en) * 2014-04-01 2015-10-08 Advantech Bioscience Farmacêutica Ltda. Stable factor viii formulations with low sugar-glycine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000210A1 (en) 1986-06-24 1988-01-14 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
ATE356198T1 (de) * 1996-10-11 2007-03-15 Invitrogen Corp Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium

Also Published As

Publication number Publication date
CA2378751A1 (en) 2001-01-18
JP4674021B2 (ja) 2011-04-20
ATE310533T1 (de) 2005-12-15
WO2001003726A1 (en) 2001-01-18
AR024735A1 (es) 2002-10-23
CA2378751C (en) 2012-11-06
DE60024268D1 (de) 2005-12-29
US6599724B1 (en) 2003-07-29
EP1194161B1 (en) 2005-11-23
JP2003504345A (ja) 2003-02-04
DE60024268T2 (de) 2006-08-03
NZ516400A (en) 2004-02-27
AU6193300A (en) 2001-01-30
ES2252028T3 (es) 2006-05-16
DK1194161T3 (da) 2006-02-13
NO330048B1 (no) 2011-02-07
NO20020120L (no) 2002-02-28
AU780415B2 (en) 2005-03-17
NO20020120D0 (no) 2002-01-10
EP1194161A1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
CY1104986T1 (el) Σταθερα σκευασματα παραγοντα viii
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
DE69637147D1 (de) Transportproteine und deren verwendungen
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
DE60144145D1 (de) Subtilisin-variante
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
CY1106135T1 (el) Μεσο για την ελευθepη απο πρωτεϊνη και ελευθepη απο ορο καλλιεργεια κυτταρων
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
CY1106111T1 (el) Ανασυνδυασμενος σταθepος κυτταρικος κλωνος, η παρασκευη και χρησιμοποιηση του
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE215125T1 (de) ßHEAT SHOCKß-PROTEINE UND BEHANDLUNG VON TUMOREN
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CY1113477T1 (el) Ετερολογος εκφραση πρωτεϊνων της neisseria
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
CY1105842T1 (el) Τροποποιημενες v πρωτεϊνες ιου ιλαρας
CY1105097T1 (el) Χρηση παραγωγων ν-φαινυλο-2-πυριμιδιναμινης στην αγωγη εναντι φλεγμονωδων ασθενειων
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
DK1255845T3 (da) Modificerede cytokiner til anvendelse i cancerterapi
AR246983A1 (es) Plasmido dna recombinante, linea celular y procedimiento para producir beta-ngf humano.
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner